Welcome to OncoDaily Weekly, your quick roundup of the most important developments in oncology from the past two weeks. From regulatory decisions and new drug approvals to breakthrough research, expert insights, and global conversations on cancer care, here are the key stories shaping oncology from February 23 to March 8, 2026.
How I Treat Gallbladder and Bile Duct Cancer in 2026: OncoDaily Virtual Summit
The first week began with the OncoDaily Virtual Summit. Held on February 28, during Gallbladder and Bile Duct Cancer Awareness Month, the summit brought together leading experts from across continents to discuss current standards of care, emerging therapies, precision medicine strategies, and evolving clinical practices shaping the future of hepatobiliary oncology.
Here is Key Insights from the OncoDaily Global Summit: How I Treat Gallbladder and Bile Duct Cancer in 2026
The ASCO GU 2026
The ASCO Genitourinary Cancers Symposium 2026 took place February 26–28 in San Francisco, bringing together global experts to discuss the latest advances in genitourinary oncology under the theme “Patient-Centered Care: From Discovery to Delivery.”
OncoDaily covered key highlights and major takeaways from the meeting, featuring important clinical updates, expert insights, and discussions shaping the future of prostate, bladder, and kidney cancer care.
Here are 15 interesting and informational posts that you shouldn’t miss from different professionals that visited and participated in the ASCO GU 2026.
Amol Akhade highlighted key discussions from ASCO Genitourinary Cancers Symposium 2026, focusing on results from the KEYNOTE-B15 study and ongoing questions around crossover and treatment sequencing in muscle-invasive bladder cancer (MIBC).
Neeraj Agarwal highlighted several studies presented at the ASCO Genitourinary Cancers Symposium 2026, focusing on treatment patterns, emerging biomarkers, and supportive care in genitourinary cancers.
Shilpa Gupta highlighted key discussions from the ASCO Genitourinary Cancers Symposium 2026, focusing on the importance of overall survival, quality of life, and strategic treatment combinations in advancing genitourinary cancer care.
FDA-Related Updates and Practice-Changing Evidence
Individualized Therapies for Ultra-Rare Diseases 2026 – FDA released draft guidance introducing a new regulatory framework to accelerate the development and approval of individualized therapies for patients with ultra-rare diseases, marking a shift toward evaluating treatments designed for single patients or very small populations where traditional trials are often not feasible.
FDA Grants Full Approval of BRAFTOVI Combination Regimen in 1L Metastatic Colorectal Cancer – BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for adults with BRAF V600E–mutated metastatic colorectal cancer, based on results from the Phase 3 BREAKWATER trial.
MONALEESA Trial – It proved that targeting the cell cycle in HR-positive metastatic breast cancer extends life across populations, across lines of therapy, and across age groups. More than a decade ago, HR-positive metastatic disease was described as manageable.
Top 10 Colorectal Cancer Updates – Don’t Miss These Important Developments
MonarchE Trial – How Abemaciclib Changed the Adjuvant Landscape in High-Risk HR+ Early Breast Cancer
LITESPARK-022 Update – Adjuvant Belzutifan + Pembrolizumab in High-Risk Clear Cell Renal Cell Carcinoma
KEYNOTE-B15: Perioperative Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer – EV + pembrolizumab significantly improves EFS and OS versus standard cisplatin-based therapy in MIBC.This is the first successful non-platinum perioperative strategy to outperform historical standard therapy.
Marty Makary: Approved a MM Drug Just 55 Days After the Application Was Filed
MOONLIGHT Trial – Testing Dual Checkpoint Blockade and Triplet Chemoimmunotherapy in 1L Advanced Gastroesophageal Adenocarcinoma
SURE-02 Trial – Neoadjuvant Sacituzumab Govitecan + Pembrolizumab in Muscle-Invasive Bladder Cancer
Elections and Role Changes
Vivek Subbiah, MD, has been appointed the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. He will lead our Early Drug Development Program to expand access to innovative treatments for Stanford cancer patients, with a focus on phase 1 clinical trials, biomarker-driven study design, targeted therapeutics, and rare cancers.
The Medical Oncology Association of Southern California (MOASC) announced Sumanta Kumar Pal as its new President, highlighting his leadership in advancing education, advocacy, and community within the oncology field.
Pal also invited input from Southern California colleagues while planning the organization’s upcoming annual board meeting agenda, including the potential launch of a one-day career development workshop for fellows and junior faculty.
Prof. Gevorg Tamamyan Joins the London Global Cancer Week Steering Group – Tamamyan, Co-Founder and Editor-in-Chief of OncoDaily and Professor of Haematology and Paediatric Oncology at Yerevan State Medical University, brings extensive experience in global oncology leadership and collaboration. Organizers noted that his global perspective and commitment to knowledge sharing will help strengthen the reach and impact of London Global Cancer Week as it continues to expand internationally.
Giuseppe Curigliano, President-Elect of European Society for Medical Oncology and Editorial Board Member at OncoDaily, was honored among 150 Italians featured by Corriere della Sera for their connection to the history of Milan. Curigliano described the recognition as a meaningful tribute to the city that shaped his career and professional journey.
Arun Krishna has been appointed Area Vice President, Asia at AstraZeneca, starting March 1, 2026. Krishna previously led the company’s U.S. Lung Cancer business and said he looks forward to working with regional teams to expand access and innovation in cancer care across Asia.
Joanna Metzner-Sadurski has been invited to serve on the Health Policy Committee of the American Society of Clinical Oncology. Metzner-Sadurski said the role will allow her to contribute to discussions on health policy, access to care, and patient communication in oncology, particularly for community-based cancer care.
Maximilian Merz of Memorial Sloan Kettering Cancer Center has been awarded $2.3 million from the Hector Foundationto study how CAR T cells and bispecific antibodies affect the immune system in patients with multiple myeloma. The research, conducted with collaborators from Leipzig University Medical Center, was published in Cancer Cell.
HPV Awareness Day 2026: Why It Matters More Than Ever
Every year on March 4, the global health community observes International HPV Awareness Day, a moment dedicated to spotlighting one of the most common yet most misunderstood viral infections in the world: Human Papillomavirus (HPV).
OncoDaily TV
Over the past two weeks, OncoDaily TV also featured a series of engaging YouTube videos, bringing expert discussions, interviews, and insights from leading voices in oncology. These conversations covered key clinical advances, emerging research, and important perspectives shaping the future of cancer care.
How to fundraise 2 Billion dollars? The secret of Christopher Clinton Conway
In this episode of OncoInfluencers, host Gevorg Tamamyan sits down with Christopher Clinton Conway — one of the most influential figures in global philanthropy, biomedical fundraising, and nonprofit leadership. With 30+ years of experience, Conway has helped raise over $2 billion for medical research, the arts, global health, and humanitarian work.
From securing President Carter’s Nobel Peace Prize, to shaping the future of pediatric cancer and Alzheimer’s research, to mentoring the next generation through the Chan Zuckerberg Initiative, Conway brings unparalleled insight into what it means to build impact at scale.
When Modern Medicine Meets Spontaneous Healing: Dr. Jeff Rediger
In this powerful episode of Into the Body, host, Dr. Aleksandra Filipovic sits down with Harvard-trained psychiatrist and author Jeffrey Rediger to explore one of the most provocative questions in medicine: What if healing is not a miracle, but a pattern we have yet to fully study? Dr. Rediger, author of the bestselling book Cured, has spent decades researching cases of spontaneous remission – patients who recover from incurable illnesses against all medical odds.
Cancer Treatment Revolution: The Device That Could Change Everything
Dr. Roupen Odabashian, with special guests Dr. Boris C. Pasche president and Chief Executive Officer of the Barbara Ann Karmanos Cancer Institute and chair of the Department of Oncology at Wayne State University, and Dr. Anthony F. Shields, Professor of Medicine at Karmanos Cancer Institute and Wayne State University School of Medicine in Detroit, Michigan, as they explore a groundbreaking approach to cancer treatment using the TheraBionic Inc., an FDA-approved therapy.
“This Is the Most Exciting Time in Cancer Research” – Dr. William Dahut
Another episode of OncoInfluencers! In this episode , host Dr. Gevorg Tamamyan sits down with Dr. William Dahut, the Chief Scientific Officer at the American Cancer Society. Dr. Dahut shares his remarkable journey from being a first-year medical student to leading transformative cancer research efforts. With decades of experience in oncology and a pivotal role at the National Cancer Institute, Dr. Dahut discusses his contributions to prostate cancer research, mentorship in the field, and the exciting future of cancer prevention and early detection.
Written by Nare Hovhannisyan, MD